Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D89BQK
|
|||
| Drug Name |
SAP-001
|
|||
| Indication | Gout [ICD-11: FA25; ICD-10: M10] | Phase 2 | [1] | |
| Company |
Shanton Pharma Shanghai, China
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucose transporter type 9 (GLUT9) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05690204) A Phase 2B Study to Evaluate the Efficacy and Safety in Combination With Standard of Care in Adult Subjects With Gout, and Hyperuricemia Refractory to Conventional XOI Therapy. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Shanton Pharma Shanghai, China | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.